We are studying a new treatment approach using nivolumab followed by chemotherapy for patients with Hodgkin's lymphoma that hasn't responded to previous therapy. The goal is to see if this combination improves treatment outcomes and safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Refractory Hodgkin Lymphoma is a type of cancer that occurs when Hodgkin lymphoma does not respond to initial treatments, leading to persistent or returning symptoms. It can be challenging to treat and may require alternative therapies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.